SOURCE: Lipomics Technologies, Inc.

July 16, 2007 08:00 ET

Lipomics Technologies to Partner With UC San Diego in Insulin Resistance and Weight Loss Research

Lipomics to Advance Diagnostic Development Programs

WEST SACRAMENTO, CA--(Marketwire - July 16, 2007) - Lipomics Technologies, Inc., a privately held company that specializes in clinical diagnostic development, announced today that it has entered into an agreement with The University of California, San Diego. The collaboration will focus on clinical investigations aimed at identifying mechanisms underlying the pathogenesis of non-insulin dependent diabetes mellitus (NIDDM), obesity, and other disorders of insulin resistance. Studies are also in progress to identify the relative role of each organ system (muscle, liver and fat) to the pathophysiology of NIDDM.

The company will collaborate on basic and clinical research programs from the lab of Jerrold Olefsky, MD, Associate Dean for Scientific Affairs at the University. "I am very enthusiastic about this new collaboration and think that the data generated through the Lipomics technology will help advance our scientific work," said Dr. Olefsky.

"This collaboration is of special strategic interest to us as we continue to establish our clinical diagnostic development programs. We are very pleased to be working with Dr. Olefsky and the University of California, San Diego," said Meeta Patnaik, chief medical officer at Lipomics.

Lipomics will retain certain rights to develop diagnostic applications based on the data from the studies. Lipomics seeks to partner with academic institutions and drug companies to advance its goal of developing diagnostic tests for metabolic diseases.

About Lipomics

Lipomics Technologies provides industry-leading metabolic assessments for drug research, clinical diagnostics and personalized medicine. The Company's proprietary analytical technologies generate comprehensive, accurate and quantitative profiles of lipid metabolites.

A broad range of bioinformatics and analytical tools map these profiles to the underlying biochemical pathways. Through these tools, Lipomics delivers deep and rich knowledge about biological and metabolic changes induced by disease, drug action, nutritional or lifestyle influences.

In partnership with pharmaceutical, biotechnology and nutrition companies, Lipomics uses its technologies to discover new diagnostic biomarkers, improve drug discovery, develop companion diagnostics and enable individualized health management.

More information about Lipomics can be found at www.lipomics.com.

Contact Information

  • EDITORIAL CONTACTS:

    Sarina Chohan
    (916) 371-7974
    Email Contact

    Agency Contact
    Doug Forsyth
    Alchymia Communications®
    (541) 482-8744
    Email Contact